CFO
NAUT icon

Callan Family Office’s Nautilus Biotechnolgy NAUT Stock Holding History

Callan Family Office’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48.6K Hold
25,970
– – ﹤0.01% 1195
2026
Q1 		$101K Hold
25,970
– – ﹤0.01% 1092
2025
Q4 		$50.6K Buy
25,970
+11,140
+75% +$18.3K ﹤0.01% 1089
2025
Q3 		$12.5K Sell
14,830
-34,064
-70% -$25K ﹤0.01% 848
2025
Q2 		$35.4K Buy
+48,894
New +$36.7K ﹤0.01% 902

Other funds holding NAUT

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
CM
Cercano Management Bellevue, Washington $750M AUM 25.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return

Callan Family Office's NAUT Position: Q2 2026 in Review

Callan Family Office held its Nautilus Biotechnolgy (NAUT) position steady in Q2 2026 at 25,970 shares worth $48.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1195.

Callan Family Office first reported a position in NAUT in Q2 2025 and has held it in 5 quarters since. The position peaked at $101K in Q1 2026. 93 funds tracked by Wall St. Rank hold NAUT as of Q2 2026.

  • Callan Family Office held 25,970 shares of Nautilus Biotechnolgy worth $48.6K as of Q2 2026.
  • Callan Family Office left its Nautilus Biotechnolgy share count unchanged in Q2 2026.
  • Nautilus Biotechnolgy made up ﹤0.01% of Callan Family Office's portfolio in Q2 2026, its #1195 holding.
  • Callan Family Office first reported a position in Nautilus Biotechnolgy in Q2 2025 and has held it in 5 quarters since.
  • Callan Family Office's Nautilus Biotechnolgy position peaked at $101K in Q1 2026.
  • 93 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.